Skip to content
Study details
Enrolling now

DOMINICA Trial

AstraZeneca
NCT IDNCT05692180ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

200

Study length

about 9.1 years

Ages

6–18

Locations

28 sites in AL, AR, AZ +16

What this study is about

This trial is testing benralizumab, a drug given by injection, in children with severe asthma. The goal is to see if benralizumab helps reduce the frequency of asthma attacks compared to a placebo.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Benralizumab
  • 2.Take Placebo

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

benralizumab

Endpoints

Secondary: Change from baseline, during the DB treatment period in Asthma symptom score, Change from baseline, during the DB treatment period in Interviewer-Administered Version of the Asthma Control Questionnaire (ACQ-IA), Change from baseline, during the DB treatment period in Paediatric Asthma Quality of Life Questionnaire-Interviewer Administered (PAQLQ-IA) total score, Change from baseline, during the DB treatment period in night-time awakenings due to asthma, Change from baseline, during the DB treatment period in peak expiratory flow (PEF), Change from baseline, during the DB treatment period in rescue medication use, Change from baseline, during the DB treatment period, in spirometry, for post-bronchodilator FEV1, Change from baseline, during the DB treatment period, in spirometry, for pre-dose/pre-bronchodilator forced expiratory volume in one second (FEV1)

Body systems

Respiratory